期刊
ANTIVIRAL RESEARCH
卷 64, 期 2, 页码 79-83出版社
ELSEVIER
DOI: 10.1016/j.antiviral.2004.07.002
关键词
resiquimod; immunomodulation; genital herpes; herpes simplex virus type 2
Genital herpes is one of the most common sexually transmitted diseases worldwide. Currently, there are three FDA-approved nucleotide analogs and other therapies such as foscarnet and cidofovir used to treat genital herpes. Resiquimod, the latest immune response modifier (IRM), has shown in vivo evidence of efficacy against herpes simplex virus (HSV) type 2. The first clinical trial involving resiquimod demonstrated that it reduced the recurrence rate of genital herpes, but phase III trials were suspended due to lack of efficacy. Resiquimod shows promise for other viral infections and as a vaccine adjuvant. (C) 2004 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据